论文部分内容阅读
目的比较美托洛尔与地尔硫卓治疗心肌反复梗死患者的疗效。方法40例急性心肌反复梗死患者随机分成两组,一组给予美托洛尔6.25 mg,口服,1次/d,另一组给地尔硫卓30 mg,口服,1次/d。疗程均为1个月。结果两组患者短期死亡率没有明显差别(P>0.05),美托洛尔组的疼痛症状缓解,疼痛再发和心衰的减少均显著优于地尔硫卓组(P<0.05)。结论小剂量美托洛尔选择性阻断β1受体,降低心肌的耗氧量,有对抗儿茶酚胺的心脏毒性作用,在防止心肌梗死的面积扩大和改善症状方面优于地硫尔卓,其长期效果仍需继续观察。
Objective To compare the efficacy of metoprolol and diltiazem in patients with recurrent myocardial infarction. Methods Forty patients with acute myocardial infarction were randomly divided into two groups. One group received metoprolol 6.25 mg orally once a day, and the other group received diltiazem 30 mg orally once daily. Treatment are 1 month. Results There was no significant difference in short-term mortality between the two groups (P> 0.05). Metoprolol group had significantly better pain relief, pain recurrence and heart failure than did diltiazem group (P <0.05). Conclusion Low dose metoprolol selectively blocks β1 receptor, reduces myocardial oxygen consumption, has the cardiotoxic effect against catecholamines, and is superior to diltiazem in preventing myocardial infarction area expansion and improving symptoms. Its long-term The effect still needs to be observed.